Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication

• Status: Completed
• Trial end date: 2019-09-28
• Target enrollment: 0
• Participant gender: All

Summary

In this randomized controlled trial, we investigate the effect of 10-day bismuth quadruple therapy in comparison with that of 7-day PPI-based standard triple as 1st line treatment for H. pylori.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Cancer Center, Korea
• Treatments: Bismuth; Clarithromycin

Criteria

Inclusion Criteria:

• Men and women aged 18 or more including following conditions

• Family history of gastric cancer

• Post endoscopic resection status for early gastric cancer or adenoma

• Peptic ulcer disease (benign gastric ulcer and duodenal ulcer)

• Chronic gastritis

• Non-ulcer dyspepsia

• Healthy adults who want to receive H. pylori treatment

• H. pylori positive by urea breath test, histology, or rapid urease test

Exclusion Criteria:

• History of H. pylori eradication therapy

• History of stomach operation

• Other organ cancer within 5 years

• Liver cirrhosis or Hepatic insufficiency

• Renal insufficiency

• Current treatment for serious medical condition which may hinder participation

• Contraindication or allergy history for H. pylori treatment regimens

• Mental incompetence to understand and sign informed consent

• Incompatible conditions to be included into the trial by investigators' decision

• Inability to provide an informed consent

• History of treatment for peptic ulcer disease